SCHEMBL3237652

SCHEMBL3237652

CCOC(=O)C1CCCC1(C)N

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.37
ALDH1A1 P00352 4/20 0.37
LMNA P02545 1/20 0.36
PPM1B O75688 1/20 0.36
PTPN1 P18031 1/20 0.36
PPP1CC P36873 1/20 0.36
LGMN Q99538 1/20 0.35
POLB P06746 1/20 0.35
KDM4E B2RXH2 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
CYP1A2 P05177 1/20 0.35
PSEN1 P49768 1/20 0.35
PSEN2 P49810 1/20 0.35
APH1B Q8WW43 1/20 0.35
NCSTN Q92542 1/20 0.35
APH1A Q96BI3 1/20 0.35
PSENEN Q9NZ42 1/20 0.35
SMYD3 Q9H7B4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11042018 0.80 CYP1A2 (0.41) MAPTALDH1A1LMNAPPM1BPTPN1
SCHEMBL17971804 0.77 MAPT (0.38) MAPTALDH1A1LMNAPPM1BPTPN1
SCHEMBL14248496 0.77 ALDH1A1 (0.41) MAPTALDH1A1LMNAPPM1BPTPN1
SCHEMBL18828224 0.77 ALDH1A1 (0.38) MAPTALDH1A1LMNAPPM1BPTPN1
SCHEMBL1230557 0.74 ALDH1A1 (0.41) MAPTALDH1A1PPM1BPTPN1PPP1CC
SCHEMBL16967405 0.74 SLC1A2 (0.44) ALDH1A1LMNAKDM4ETDP1CYP1A2
SCHEMBL16967403 0.74 SLC1A2 (0.44) ALDH1A1LMNAKDM4ETDP1CYP1A2
SCHEMBL31472242 0.74 SLC1A2 (0.44) ALDH1A1LMNAKDM4ETDP1CYP1A2
SCHEMBL16967404 0.74 SLC1A2 (0.44) ALDH1A1LMNAKDM4ETDP1CYP1A2
SCHEMBL21950907 0.73 ALDH1A1 (0.38) MAPTALDH1A1LMNAPPM1BPTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1458392-B9 ACRIDONES AS INHIBITORS OF IMPDH ENZYME BRISTOL MYERS SQUIBB CO (US) 2010-07-28 EP disclosed
EP-1458392-B1 ACRIDONES AS INHIBITORS OF IMPDH ENZYME BRISTOL MYERS SQUIBB CO (US) 2009-09-02 EP disclosed
US-7312209-B2 Acridone inhibitors of IMPDH enzyme BRISTOL-MYERS SQUIBB COMPANY (US) 2007-12-25 US disclosed
EP-1458392-A4 ACRIDONE INHIBITORS OF IMPDH ENZYME BRISTOL MYERS SQUIBB CO (US) 2005-06-08 EP disclosed
EP-1458392-A2 ACRIDONE INHIBITORS OF IMPDH ENZYME Bristol-Myers Squibb Company (US) 2004-09-22 EP disclosed
US-20040053955-A1 Acridone inhibitors of IMPDH enzyme BRISTOL-MYERS SQUIBB COMPANY 2004-03-18 US disclosed
WO-2003059269-A2 ACRIDONE INHIBITORS OF IMPDH ENZYME BRISTOL-MYERS SQUIBB COMPANY (US) 2003-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053955-A1 Acridone inhibitors of IMPDH enzyme IMPDH2, IMPDH1, XDH MAPT 4322/4885ALDH1A1 39/4885LMNA 3692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.